Merck Animal Health is the world's third-largest animal health business and a division of Merck & Co., with $5.9 billion in 2024 sales (+4% reported, +8% constant currency) and 2025 results tracking similar growth. Operations span 140+ countries with 25 manufacturing facilities and 16 R&D centers. BRAVECTO generated $1.1 billion in 2024 sales; BRAVECTO QUANTUM received FDA approval in July 2025 as the first once-yearly parasiticide for dogs.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Strategic priorities include the $895 million De Soto, Kansas biologics expansion (commercial production beginning 2030), the BRAVECTO QUANTUM rollout, and NUMELVI (second-generation JAK inhibitor for canine pruritus, FDA-approved February 2026). The Elanco aquaculture acquisition (July 2024) expanded the aquatic species footprint. Strengths include parent-company R&D and capital depth, parasiticide and vaccine breadth, and 8 consecutive S&P Global Animal Health awards. Risks include parent-company priority allocation, manufacturing capacity gating new launches until Kansas completes, and parasiticide competition.

Topics Covered
• Corporate Overview and History
• Strategic Directions and 2026-2030 Priorities
• Financial Performance and Segment Breakdown
• SWOT Analysis
• Business Segment Analysis
• Technology and Innovation Pipeline
• M&A, Partnerships and Licensing Activity
• Competitive Positioning Against Top 10 Peers
• Strategic Conclusions and Outlook